NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
ID: 350854Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350854

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-049.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), is offering a funding opportunity for pilot studies aimed at planning clinical trials (R34) focused on heart, lung, blood, and sleep disorders. This Notice of Funding Opportunity (NOFO) seeks to gather essential data to inform the design of Phase II-IV trials, emphasizing the need for research that addresses knowledge gaps necessary for future trials. A critical requirement of the application process is the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity within scientific teams, aligning with NIH’s goals of advancing scientific innovation. The funding amount can reach up to $450,000 over three years, with key deadlines including an open submission date starting January 1, 2024, and the first application due by February 16, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-049.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI), announces a funding opportunity for pilot studies aimed at planning clinical trials (R34). This Notice of Funding Opportunity (NOFO) seeks to gather essential data to inform the design of Phase II-IV trials centered on heart, lung, blood, and sleep disorders. It encourages applications that demonstrate a clear need for research to fill knowledge gaps necessary for future trials. A critical aspect is the requirement for a Plan for Enhancing Diverse Perspectives (PEDP), promoting inclusivity and diverse scientific teams. Applications must align with NIH’s goals of advancing scientific innovation by including diverse voices in research. The budget allocations allow up to $450,000 over three years, emphasizing the importance of early application submission to correct potential errors. Key deadlines include an open date for submissions starting January 1, 2024, with the first application due February 16, 2024. The NHBLI is dedicated to supporting impactful research that addresses pressing health challenges, thus aligning the overarching goal of improving health outcomes through innovative and diverse scientific collaboration.
    Similar Opportunities
    NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for R34 Clinical Trial Pilot Studies aimed at supporting research that informs the planning of Phase II-IV clinical trials focused on heart, lung, blood, and sleep disorders. Applicants are required to demonstrate that their proposed studies are essential for the design of future trials and must include a Plan for Enhancing Diverse Perspectives (PEDP) to promote diversity within research teams. This initiative is critical for advancing clinical practice and understanding in these vital health areas, with awards of up to $450,000 available over three years. Interested applicants should submit their proposals by January 7, 2027, and can find additional information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NHLBI Early Phase Clinical Trials (R33), aimed at supporting investigator-initiated Phase I clinical trials for therapeutic and diagnostic interventions targeting heart, lung, blood, and sleep (HLBS) disorders. Applicants are required to be prepared to initiate their clinical trials within the first quarter of the project period and must demonstrate readiness in obtaining necessary regulatory approvals, including FDA and IRB, prior to the award. This funding is crucial for addressing unmet medical needs through innovative research, with a maximum budget of $1.515 million per year and a project duration of up to three years, contingent upon achieving specific milestones. Interested applicants should note the application deadline of June 4, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity (FON: PAR-24-173) aimed at supporting Phase I clinical trials for therapeutics and diagnostics related to heart, lung, blood, and sleep (HLBS) disorders in both adults and children. This initiative utilizes a bi-phasic R61/R33 award mechanism, where the R61 phase focuses on preparatory activities such as finalizing trial protocols and gathering preclinical data, while the R33 phase is dedicated to executing the clinical trial. The funding limits include up to $250,000 annually for the R61 phase and $1,515,000 for the R33 phase, with total support available for a maximum of five years. Interested applicants must adhere to NIH guidelines and submit their proposals by January 7, 2027, to be considered for this opportunity. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity aimed at supporting Phase I clinical trials for therapeutic and diagnostic interventions related to heart, lung, blood, and sleep (HLBS) disorders. This initiative seeks to accelerate the development of clinical interventions by funding investigator-initiated studies that demonstrate potential advancements in HLBS health, with a focus on ensuring that applicants are prepared to initiate trials promptly after receiving funding. The funding is capped at $1.5 million per year for a project period of up to three years, contingent on satisfactory progress and milestone completion, with applications opening on January 3, 2025, and the first due date set for February 3, 2025. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-025.html.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders," aimed at supporting investigator-initiated Phase I clinical trials for heart, lung, blood, and sleep (HLBS) disorders in both adults and children. This grant (R61/R33) facilitates funding for essential preclinical activities and the execution of clinical trials, structured in two phases: the R61 phase focuses on preparatory tasks, while the R33 phase involves the actual trial conduct, guided by specific milestones. This initiative is crucial for advancing research that addresses significant health challenges associated with HLBS disorders. Interested applicants can submit proposals starting January 3, 2025, with a maximum project period of five years, and should direct inquiries to grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-026.html.
    Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), is offering a funding opportunity titled "Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)." This grant aims to support the development and validation of innovative technologies that address significant gaps in heart, lung, blood, and sleep (HLBS) research, focusing on advancing diagnostic and therapeutic solutions with promising preliminary data. Eligible applicants include a wide range of institutions and organizations, with a budget ceiling of $350,000 in direct costs per year, and total funding commitments expected to reach $2,156,000 annually for the next three fiscal years. The application deadline is set for January 11, 2025, and further details can be found on the NIH grants website or by contacting NIH Grants Information at grantsinfo@nih.gov.
    NHLBI Program Project Applications (P01 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity for Program Project (P01) grant applications aimed at advancing research in heart, lung, and blood diseases. Applicants are required to submit proposals that include a minimum of three interrelated research projects focused on a common biomedical theme, with the option to incorporate clinical trials. This initiative is designed to foster collaborative research efforts and encourage innovative scientific directions, particularly supporting projects led by Early Stage Investigators (ESIs). The maximum funding for awarded projects is capped at $1.515 million annually, or $1.765 million if an ESI-led project is included, with a project duration of up to five years. Interested applicants can find more information and submit their proposals electronically via Grants.gov, with a closing date for applications set for September 25, 2026. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity for Single-Site Investigator-Initiated Clinical Trials (R61/R33), aimed at supporting applications for clinical trials that test therapeutic, behavioral, or prevention strategies relevant to NHLBI's mission. This funding mechanism involves a bi-phasic award structure, with an initial R61 phase focused on protocol development followed by an R33 phase for trial execution, emphasizing comprehensive project management, subject recruitment, and community engagement. The initiative is particularly significant for advancing clinical research while promoting diversity among study participants and project teams. Interested applicants can find more details and submit proposals by September 12, 2025, and should direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity for exploratory R21 grant applications focused on secondary analyses of existing human datasets related to heart, lung, blood diseases, and sleep disorders. The objective of this grant is to stimulate innovative research by utilizing existing datasets to explore novel scientific ideas and develop impactful biomedical tools and technologies, without the need for new primary data collection. This initiative is crucial for advancing public health research aligned with NHLBI priorities, with an annual funding commitment of up to $2,187,000 over three years, supporting approximately eighteen new awards each year, with a maximum of $75,000 in direct costs per application for a two-year project period. Interested applicants can find more information and application guidelines at NIH Grants, and should note that the application deadline is January 7, 2026.
    Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), is offering a federal grant opportunity titled "Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)." This program aims to support educational activities that enhance the diversity of the biomedical, behavioral, and clinical research workforce by providing research experiences and related opportunities for individuals from underrepresented groups. The initiative is crucial for addressing health disparities in cardiovascular, pulmonary, and hematologic diseases by fostering a diverse scientific workforce. Interested applicants can apply for funding up to $175,000 per year for a maximum of five years, with applications opening on December 29, 2023, and a submission deadline of August 19, 2026. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-25-001.html.